Oksana Igorevna Efremova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Oksana Igorevna Efremova has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Igor Anatolievich Zolotukhin
Pirogov Russian National Research Medical University
16 shared publications - Sergey Gennadievich Gavrilov
Savelyev University Surgical Clinic — Pirogov Russian National Research Medical University
10 shared publications - Evgeny I. Seliverstov
Institute of Surgery of the Pirogov Russian National Research Medical University
7 shared publications I. S. Lebedev
6 shared publications- Nadezhda Yurievna Mishakina
Savelyev University Surgical Clinic, Pirogov Russian National Research Medical University, Moscow, Russia
4 shared publications - A.N. Kuznetsov
Pirogov Russian National Research Medical University
3 shared publications
Latest Publications
- 12 May 2026
- Published by Springer Nature in Hernia
- Vol. 30 (1)
Abdominal binders in postoperative care: a scoping review
The objective of this study was to provide a review of the evidence base for the use of abdominal binders in patients undergoing surgical procedures involving the abdominal cavity. We followed and structured the manuscript according to the PRISMA Extension for Scoping Reviews. We performed a systematic literature search on September 30, 2025, which was limited to publications in English and Russian, across seven electronic databases: PubMed/MEDLINE, Embase, Scopus, CINAHL, ClinicalTrials.gov, and eLibrary.ru. We included only randomized controlled trials and meta-analyses as eligible study designs. We did not include meta-analyses that summarize the results of using an abdominal binder exclusively after gynecological surgeries and cesarean sections. and presented key outcomes in summary tables. We identified 28 randomized controlled trials and critically appraised five meta-analyses synthesizing evidence from these trials, which compared the use of abdominal binders versus no binder. Pooled evidence has demonstrated that the use of abdominal binders is associated with statistically significant reductions in postoperative pain and improvements in functional mobility following abdominal surgery, with benefits observed during both early and later recovery phases. These advantages were not accompanied by significant changes in pulmonary function. The evidence on the effect of the use of abdominal binders on surgical site infection has demonstrated considerable heterogeneity. Meta-analyses yield conflicting results, with findings ranging from a significant reduction in infection rates after open surgery (laparotomy) to an absence of significant differences across subgroups stratified by surgical type, approach, or binder design. The obtained results may be compromised by substantial heterogeneity in the types of surgical procedures included across randomized controlled trials and by the absence of trial sequential analysis to determine whether the accumulated evidence has reached the required information size for conclusive interpretation. The current evidence, though of low to moderate certainty, suggests that abdominal binders may serve as effective adjuncts for postoperative pain management and early mobilization. These benefits appear to be achievable without significant compromise to pulmonary function or increasing respiratory complications, although the perceived safety profile should be interpreted with caution due to limited reporting of complications in the literature.
- 12 May 2026
- Published by Springer Nature in Hernia
- Vol. 30 (1)
Abdominal binders in postoperative care: a scoping review
The objective of this study was to provide a review of the evidence base for the use of abdominal binders in patients undergoing surgical procedures involving the abdominal cavity. We followed and structured the manuscript according to the PRISMA Extension for Scoping Reviews. We performed a systematic literature search on September 30, 2025, which was limited to publications in English and Russian, across seven electronic databases: PubMed/MEDLINE, Embase, Scopus, CINAHL, ClinicalTrials.gov, and eLibrary.ru. We included only randomized controlled trials and meta-analyses as eligible study designs. We did not include meta-analyses that summarize the results of using an abdominal binder exclusively after gynecological surgeries and cesarean sections. and presented key outcomes in summary tables. We identified 28 randomized controlled trials and critically appraised five meta-analyses synthesizing evidence from these trials, which compared the use of abdominal binders versus no binder. Pooled evidence has demonstrated that the use of abdominal binders is associated with statistically significant reductions in postoperative pain and improvements in functional mobility following abdominal surgery, with benefits observed during both early and later recovery phases. These advantages were not accompanied by significant changes in pulmonary function. The evidence on the effect of the use of abdominal binders on surgical site infection has demonstrated considerable heterogeneity. Meta-analyses yield conflicting results, with findings ranging from a significant reduction in infection rates after open surgery (laparotomy) to an absence of significant differences across subgroups stratified by surgical type, approach, or binder design. The obtained results may be compromised by substantial heterogeneity in the types of surgical procedures included across randomized controlled trials and by the absence of trial sequential analysis to determine whether the accumulated evidence has reached the required information size for conclusive interpretation. The current evidence, though of low to moderate certainty, suggests that abdominal binders may serve as effective adjuncts for postoperative pain management and early mobilization. These benefits appear to be achievable without significant compromise to pulmonary function or increasing respiratory complications, although the perceived safety profile should be interpreted with caution due to limited reporting of complications in the literature.
- 30 April 2026
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 20 (2) , 120-148
Duplex Ultrasound of Lower Extremities Venous System. Consensus of Experts in Venous Disease
Duplex ultrasound (DUS) is an imaging technique that is widely used in order to assess venous system conditions in healthy subjects and in patients with chronic venous disease, deep venous thrombosis and superficial thrombophlebitis. A thoroughly performed DUS is crucially important for precise diagnostics and treatment. DUS is widely accepted as mandatory in phlebology practice. Other specialists are often in need for duplex ultrasound also in order to exclude deep venous thrombosis as a complication of different pathologic conditions. This is an updated version of guidelines developed by an expert group. The document systematizes data on the ultrasound anatomy of the veins of the lower extremities. It describes the main algorithms DUS as well as requirements for the configuration and settings of the ultrasound machine. The position of the patient during the study, ultrasound transducer placing, depending on the situation are presented. Criteria of pathologic venous reflux are discussed. DUS methodology for different venous segments are presented. A newly developed algorithms of examination of patients having different clinical scenarios are presented. The document suggests examples for formal conclusions based on the results of the ultrasound examination. A lawyer’s report based on the results of the analysis of the regulatory documentation regarding justification of the use of DUS by phlebologists in their clinical practice is presented. Guidelines are addressed to ultrasound diagnostics specialists, phlebologists, vascular specialists, general surgeons and others.
- 30 April 2026
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 20 (2) , 120-148
Duplex Ultrasound of Lower Extremities Venous System. Consensus of Experts in Venous Disease
Duplex ultrasound (DUS) is an imaging technique that is widely used in order to assess venous system conditions in healthy subjects and in patients with chronic venous disease, deep venous thrombosis and superficial thrombophlebitis. A thoroughly performed DUS is crucially important for precise diagnostics and treatment. DUS is widely accepted as mandatory in phlebology practice. Other specialists are often in need for duplex ultrasound also in order to exclude deep venous thrombosis as a complication of different pathologic conditions. This is an updated version of guidelines developed by an expert group. The document systematizes data on the ultrasound anatomy of the veins of the lower extremities. It describes the main algorithms DUS as well as requirements for the configuration and settings of the ultrasound machine. The position of the patient during the study, ultrasound transducer placing, depending on the situation are presented. Criteria of pathologic venous reflux are discussed. DUS methodology for different venous segments are presented. A newly developed algorithms of examination of patients having different clinical scenarios are presented. The document suggests examples for formal conclusions based on the results of the ultrasound examination. A lawyer’s report based on the results of the analysis of the regulatory documentation regarding justification of the use of DUS by phlebologists in their clinical practice is presented. Guidelines are addressed to ultrasound diagnostics specialists, phlebologists, vascular specialists, general surgeons and others.
- 27 September 2025
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 19 (3)
Onset, Time Course and Duration of Venoactive Drugs Effect on Venous Symptoms in Patients with Chronic Venous Disease
Onset and duration of effect of venoactive drug (VAD) and topical agent on venous symptoms are unclear. Objective — to determine onset and duration of the effect of treatment with VAD and/or local gel use on venous symptoms. Material and methods. 121 patients (C1—C3S) were included in the multicenter prospective study. First group patients received VAD with topical agent. Second group patients received VAD only. Third group patients received local agent only. Duration of therapy was 2 months. Leg’s discomfort related to venous symptoms, quality of life, effect onset, duration of the effect after therapy completion were assessed. The symptoms were registered at 10 visits: beginning of therapy, after one, two, four, six and weeks (end of therapy), 3, 4, 5 and 6 months after the start of therapy. Results. 88, 82 and 76% of patients reported complete symptoms resolution or significant improving in the first, second and third groups, respectively. The effect was increasing during the first month of therapy with 70—80% of patients with improvement by this time. Baseline discomfort level was a predictor of insufficient effect. The higher level was related to worse results (OR=0.97 (95% CI: 0.94—0.99), p=0.017). Gender, age, CEAP disease class, obesity did not affect the result. The use of a local agent alone was associated with a higher probability of symptom persistence (OR=2.89 (95% CI: 0.97—8.54), p=0.056). Symptoms increased and returned within 4 months after discontinuation of therapy. Complete return of symptoms occurred in 22, 16 and 38% of patients in the first, second and third groups, respectively by the end of the follow-up. Conclusions. A two-month course of VAD treatment (and/or local gel use) effectively alleviates venous symptoms. Next course should be prescribed between one and four months after completing the two-month course, depending on increasing of symptoms severity. The use of a local agent alone is less effective, the achieved result is less stable.
- 27 September 2025
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 19 (3)
Onset, Time Course and Duration of Venoactive Drugs Effect on Venous Symptoms in Patients with Chronic Venous Disease
Onset and duration of effect of venoactive drug (VAD) and topical agent on venous symptoms are unclear. Objective — to determine onset and duration of the effect of treatment with VAD and/or local gel use on venous symptoms. Material and methods. 121 patients (C1—C3S) were included in the multicenter prospective study. First group patients received VAD with topical agent. Second group patients received VAD only. Third group patients received local agent only. Duration of therapy was 2 months. Leg’s discomfort related to venous symptoms, quality of life, effect onset, duration of the effect after therapy completion were assessed. The symptoms were registered at 10 visits: beginning of therapy, after one, two, four, six and weeks (end of therapy), 3, 4, 5 and 6 months after the start of therapy. Results. 88, 82 and 76% of patients reported complete symptoms resolution or significant improving in the first, second and third groups, respectively. The effect was increasing during the first month of therapy with 70—80% of patients with improvement by this time. Baseline discomfort level was a predictor of insufficient effect. The higher level was related to worse results (OR=0.97 (95% CI: 0.94—0.99), p=0.017). Gender, age, CEAP disease class, obesity did not affect the result. The use of a local agent alone was associated with a higher probability of symptom persistence (OR=2.89 (95% CI: 0.97—8.54), p=0.056). Symptoms increased and returned within 4 months after discontinuation of therapy. Complete return of symptoms occurred in 22, 16 and 38% of patients in the first, second and third groups, respectively by the end of the follow-up. Conclusions. A two-month course of VAD treatment (and/or local gel use) effectively alleviates venous symptoms. Next course should be prescribed between one and four months after completing the two-month course, depending on increasing of symptoms severity. The use of a local agent alone is less effective, the achieved result is less stable.
- Open Access
- 27 August 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (9) , 1316
Daily Duration of Compression Treatment in Chronic Venous Disease Patients: A Systematic Review
Background: There are no data on the daily regimen of compression therapy in patients with chronic venous disease. This systematic review aimed to establish the optimal daily duration of compression treatment. Methods: A systematic search of CENTRAL and MEDLINE was performed to identify RCTs, non-RCTs, reviews, systematic reviews, meta-analyses, and guidelines evaluating the use of compression regimens in the treatment of varicose veins. Results: Thirty-two RCTs, three non-RCTs, four observational studies, and two crossover trials reporting the duration and regimes of compression treatment fulfilled the inclusion criteria. The daily duration of compression was reported in patients after invasive treatment, for venous ulcer treatment, in patients with venous symptoms. The quality of the studies varied. We could not conduct a meta-analysis due to the heterogeneity of the research data and their quality. Twenty-three studies reported results of compression usage after invasive procedures. Eight studies reported daily duration regimens in patients with venous ulcers. Nine studies reported the impact of compression on venous symptoms and/or edema or limb volume change. One study was conducted to assess if compression improves QoL in venous patients. While there was a clear difference found in the daily duration depending on the clinical scenario, no data in support of exact regimens were found. Conclusions: There are no reliable data supporting exact daily regimens of compression treatment in various cohorts of CVD patients.
- 27 August 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (9) , 1316
Open AccessDaily Duration of Compression Treatment in Chronic Venous Disease Patients: A Systematic Review
Background: There are no data on the daily regimen of compression therapy in patients with chronic venous disease. This systematic review aimed to establish the optimal daily duration of compression treatment. Methods: A systematic search of CENTRAL and MEDLINE was performed to identify RCTs, non-RCTs, reviews, systematic reviews, meta-analyses, and guidelines evaluating the use of compression regimens in the treatment of varicose veins. Results: Thirty-two RCTs, three non-RCTs, four observational studies, and two crossover trials reporting the duration and regimes of compression treatment fulfilled the inclusion criteria. The daily duration of compression was reported in patients after invasive treatment, for venous ulcer treatment, in patients with venous symptoms. The quality of the studies varied. We could not conduct a meta-analysis due to the heterogeneity of the research data and their quality. Twenty-three studies reported results of compression usage after invasive procedures. Eight studies reported daily duration regimens in patients with venous ulcers. Nine studies reported the impact of compression on venous symptoms and/or edema or limb volume change. One study was conducted to assess if compression improves QoL in venous patients. While there was a clear difference found in the daily duration depending on the clinical scenario, no data in support of exact regimens were found. Conclusions: There are no reliable data supporting exact daily regimens of compression treatment in various cohorts of CVD patients.
- Open Access
- 30 July 2023
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
- Vol. 38 (9) , 622-627
Low concentration of sodium tetradecyl sulfate and hypertonic glucose solution for the treatment of telangiectasia: A prospective randomized clinical trial
Objectives: This study aimed to compare telangiectasias disappearance after sclerotherapy with hypertonic glucose (HG) and different concentrations of sodium tetradecyl sulfate (STS). Methods: Women aged 18–70 years with telangiectasias were included. The primary efficacy endpoint was telangiectasia disappearance. The clearing of vessels was assessed using a six-point scale (from 0 to 5). Results: A total of 116 women completed an 8-week follow-up: 31, 27, 25, and 33 were in the HG 75%, STS 0.05%, STS 0.1%, and STS 0.15% groups, respectively. The median score of vein disappearance was significantly lower in the STS 0.05% (3, 0.25–4), STS 0.1% (3, 1.25–4), and STS 0.15% (4, 2–4) groups than in the HG group (4, 3–5) after 56 days, p = .00002. Conclusion: Sclerotherapy of telangiectasias with 75% HG showed significantly better results than low concentrations of STS. Trial registration: ClinicalTrials.gov NCT04132323.
- 30 July 2023
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
- Vol. 38 (9) , 622-627
Open AccessLow concentration of sodium tetradecyl sulfate and hypertonic glucose solution for the treatment of telangiectasia: A prospective randomized clinical trial
Objectives: This study aimed to compare telangiectasias disappearance after sclerotherapy with hypertonic glucose (HG) and different concentrations of sodium tetradecyl sulfate (STS). Methods: Women aged 18–70 years with telangiectasias were included. The primary efficacy endpoint was telangiectasia disappearance. The clearing of vessels was assessed using a six-point scale (from 0 to 5). Results: A total of 116 women completed an 8-week follow-up: 31, 27, 25, and 33 were in the HG 75%, STS 0.05%, STS 0.1%, and STS 0.15% groups, respectively. The median score of vein disappearance was significantly lower in the STS 0.05% (3, 0.25–4), STS 0.1% (3, 1.25–4), and STS 0.15% (4, 2–4) groups than in the HG group (4, 3–5) after 56 days, p = .00002. Conclusion: Sclerotherapy of telangiectasias with 75% HG showed significantly better results than low concentrations of STS. Trial registration: ClinicalTrials.gov NCT04132323.
- 23 April 2023
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 17 (4)
Compression After Sclerotherapy in C1 Patients: Impact on Outcomes and Complications Rate
We analyzed literature data on possible impact of elastic compression on the results of sclerotherapy in patients with reticular varicose veins and telangiectasias. Clinical outcomes and quality of life after sclerotherapy were analyzed depending on postoperative compression. In addition, a special attention was paid to such important complications of sclerotherapy as hyperpigmentation and telangiectatic matting. Literature data confirm heterogeneous results regarding clinical effect of compression after sclerotherapy. There still lack of data to draw any robust conclusions. In most studies, compression is recognized as a method improving cosmetic results and reducing the risk of complications such as hyperpigmentation and telangiectatic matting. However, not all studies confirm such effects. Well-planned studies are necessary to evaluate compression therapy in C1 patients.
- 23 April 2023
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 17 (4)
Compression After Sclerotherapy in C1 Patients: Impact on Outcomes and Complications Rate
We analyzed literature data on possible impact of elastic compression on the results of sclerotherapy in patients with reticular varicose veins and telangiectasias. Clinical outcomes and quality of life after sclerotherapy were analyzed depending on postoperative compression. In addition, a special attention was paid to such important complications of sclerotherapy as hyperpigmentation and telangiectatic matting. Literature data confirm heterogeneous results regarding clinical effect of compression after sclerotherapy. There still lack of data to draw any robust conclusions. In most studies, compression is recognized as a method improving cosmetic results and reducing the risk of complications such as hyperpigmentation and telangiectatic matting. However, not all studies confirm such effects. Well-planned studies are necessary to evaluate compression therapy in C1 patients.
- 24 March 2023
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 17 (1)
Extended Compression Decreases Hyperpigmentation Rate after Sclerotherapy in Patients with Spider Veins and Telangiectasias
Objective. To compare the results of short-term and extended compression therapy after sclerotherapy in patients with reticular varicose veins and telangiectasias. Material and methods. A comparative non-randomized study included 72 patients with reticular varicose veins and/or telangiectasias (class C1) who underwent sclerotherapy with polidocanol. In the first group, compression for 3 days after each procedure around the clock was prescribed. Patients did not use compression between procedures and after completion of treatment. In the 2nd group, knitwear wearing regimen immediately after procedure was similar. Then, class 2 compression stockings were used for 5 days a week between procedures and after completion of sclerotherapy course. The endpoints were skin hyperpigmentation and telangiectatic matting rates in 4 months after sclerotherapy onset. Severity of hyperpigmentation and comfort of compression stocking wearing were assessed. Results. There were no significant between-group differences in characteristics of patients. In 4 months after onset of treatment, hyperpigmentation rate was 29% and 6% in both groups, respectively (p=0.011). Telangiectatic matting rates were 17.6 and 2.8%, respectively (p=0.052). Severity of hyperpigmentation according to a 4-point scale was 0.53±0.8 and 0.08±0.36, respectively (p=0.041). Patients well tolerated long-term compression. There were no cases interrupted compression. Conclusion. Incidence and severity of hyperpigmentation, as well as telangiectatic matting rate were significantly lower after prolonged compression therapy in patients with reticular varicose veins and telangiectasias.
- 24 March 2023
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 17 (1)
Extended Compression Decreases Hyperpigmentation Rate after Sclerotherapy in Patients with Spider Veins and Telangiectasias
Objective. To compare the results of short-term and extended compression therapy after sclerotherapy in patients with reticular varicose veins and telangiectasias. Material and methods. A comparative non-randomized study included 72 patients with reticular varicose veins and/or telangiectasias (class C1) who underwent sclerotherapy with polidocanol. In the first group, compression for 3 days after each procedure around the clock was prescribed. Patients did not use compression between procedures and after completion of treatment. In the 2nd group, knitwear wearing regimen immediately after procedure was similar. Then, class 2 compression stockings were used for 5 days a week between procedures and after completion of sclerotherapy course. The endpoints were skin hyperpigmentation and telangiectatic matting rates in 4 months after sclerotherapy onset. Severity of hyperpigmentation and comfort of compression stocking wearing were assessed. Results. There were no significant between-group differences in characteristics of patients. In 4 months after onset of treatment, hyperpigmentation rate was 29% and 6% in both groups, respectively (p=0.011). Telangiectatic matting rates were 17.6 and 2.8%, respectively (p=0.052). Severity of hyperpigmentation according to a 4-point scale was 0.53±0.8 and 0.08±0.36, respectively (p=0.041). Patients well tolerated long-term compression. There were no cases interrupted compression. Conclusion. Incidence and severity of hyperpigmentation, as well as telangiectatic matting rate were significantly lower after prolonged compression therapy in patients with reticular varicose veins and telangiectasias.
- 24 March 2023
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 17 (1)
Venoactive Drug Treatment or Compression Stockings in Warm Weather Season in Symptomatic Patients with Chronic Venous Disease
Adherence to compression therapy is low in many patients, especially in warm weather. Venoactive drug (VAD) therapy alone may be an option in patients with symptomatic chronic venous disease (CVD). Objective. To compare VAD therapy and compression therapy in symptomatic CVD patients during warm season. Material and methods. A comparative non-randomized study included 60 patients with CVD class C1S, C2S and C3S. Patients were recruited between May and September. VAD containing micronized diosmin 900 mg and hesperidin 100 mg one tablet per day for 90 days was prescribed in 41 patients (main group). Compression stockings were recommended in 19 patients (control group). End-points were discomfort in the lower legs related to CVD symptoms, quality of life (QoL) and venous symptoms. Results. Legs discomfort decreased from 52±22 to 32±19 (p<0.0001) after VAD therapy and from 49±21 to 42±17 (p=0.02) after compression therapy. VAD therapy resulted more significant regression of discomfort (38% and 14%, respectively, p<0.001). QoL improved from 64±16 to 78±12 (p<0.0001) after VAD treatment and from 72±14 to 77±8 (p=0.02) after compression therapy. Mean improvement was 22% and 5%, respectively (p<0.001). All venous symptoms decreased significantly after medical therapy. In the main group, 32 (78%) patients were adherent to VAD treatment, and only 5 (26.4%) patients complied with compression therapy. Conclusion. VAD therapy alone significantly reduces venous symptoms and improves QoL in warm weather. VAD treatment alone can be recommended as an alternative to compression therapy in warm season.
- 24 March 2023
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 17 (1)
Venoactive Drug Treatment or Compression Stockings in Warm Weather Season in Symptomatic Patients with Chronic Venous Disease
Adherence to compression therapy is low in many patients, especially in warm weather. Venoactive drug (VAD) therapy alone may be an option in patients with symptomatic chronic venous disease (CVD). Objective. To compare VAD therapy and compression therapy in symptomatic CVD patients during warm season. Material and methods. A comparative non-randomized study included 60 patients with CVD class C1S, C2S and C3S. Patients were recruited between May and September. VAD containing micronized diosmin 900 mg and hesperidin 100 mg one tablet per day for 90 days was prescribed in 41 patients (main group). Compression stockings were recommended in 19 patients (control group). End-points were discomfort in the lower legs related to CVD symptoms, quality of life (QoL) and venous symptoms. Results. Legs discomfort decreased from 52±22 to 32±19 (p<0.0001) after VAD therapy and from 49±21 to 42±17 (p=0.02) after compression therapy. VAD therapy resulted more significant regression of discomfort (38% and 14%, respectively, p<0.001). QoL improved from 64±16 to 78±12 (p<0.0001) after VAD treatment and from 72±14 to 77±8 (p=0.02) after compression therapy. Mean improvement was 22% and 5%, respectively (p<0.001). All venous symptoms decreased significantly after medical therapy. In the main group, 32 (78%) patients were adherent to VAD treatment, and only 5 (26.4%) patients complied with compression therapy. Conclusion. VAD therapy alone significantly reduces venous symptoms and improves QoL in warm weather. VAD treatment alone can be recommended as an alternative to compression therapy in warm season.
- 24 March 2023
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 17 (1)
Response to Comment to the Article “Does the Use of Prognostic Scales and Clinical Guidelines Always Guarantee the Survival of Patients with Massive Pulmonary Embolism”
Response to Comment to the Article “Does the Use of Prognostic Scales and Clinical Guidelines Always Guarantee the Survival of Patients with Massive Pulmonary Embolism”.
- 24 March 2023
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 17 (1)
Response to Comment to the Article “Does the Use of Prognostic Scales and Clinical Guidelines Always Guarantee the Survival of Patients with Massive Pulmonary Embolism”
Response to Comment to the Article “Does the Use of Prognostic Scales and Clinical Guidelines Always Guarantee the Survival of Patients with Massive Pulmonary Embolism”.
- Open Access
- 20 November 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (11) , 1933
Complications and Adverse Events of Gonadal Vein Embolization with Coils
Background: The efficacy and safety of gonadal vein embolization (GVE) with coils in the treatment of pelvic venous disease (PeVD) has not been fully investigated, and the outcomes after GVE do not always meet expectations of both doctors and patients. The study was aimed at assessing the incidence and causes of the complications after GVE with coils in patients with PeVD. Methods: This retrospective cohort study included 150 female patients with PeVD who underwent GVE with coils in 2000–2020. A total of 4975 patients with chronic pelvic pain (CPP) were examined, of which 1107 patients had the PeVD-related CPP and 305 underwent surgical or endovascular interventions on the gonadal veins. Complication rates were evaluated 30 days after GVE and classified according to the Society for Interventional Radiology (SIR) adverse event classification system. The pain severity before and after GVE was assessed using a visual analogue scale (VAS). All patients underwent duplex ultrasound after GVE, while patients with persisting pain syndrome and suspected perforation of the gonadal vein were also evaluated using computed tomographic venography. Results: At 30 days after GVE, the CPP was decreased in 109 (72.6%) patients (from 8.2 ± 1.5 at baseline to 1.7 ± 0.8 scores, p = 0.0001) and persisted in 41 (27.4%) patients (mean change from 8.1 ± 0.7 at baseline to 7.8 ± 0.4 scores; p = 0.71). Post-embolic syndrome (PES) occurred in 22% of patients and was completely resolved in 1 month after GVE. The efficacy of GVE in the CPP relief after resolving PES was 94.6%. The GVE complications were identified in 52 (34.6%) patients. Minor complications included access-site hematoma (4%) and allergic reactions (1.3%), and major complications included protrusion of coils (5.3%), thrombosis of the parametrial/uterine veins (21.3%) and deep veins of the calf (2.7%). Conclusions: Gonadal vein embolization with coils in the treatment of PeVD is associated with the development of specific complications and adverse events. The most common complication was pelvic vein thrombosis. Post-embolization syndrome should be considered as an adverse event of this procedure.
- 20 November 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (11) , 1933
Open AccessComplications and Adverse Events of Gonadal Vein Embolization with Coils
Background: The efficacy and safety of gonadal vein embolization (GVE) with coils in the treatment of pelvic venous disease (PeVD) has not been fully investigated, and the outcomes after GVE do not always meet expectations of both doctors and patients. The study was aimed at assessing the incidence and causes of the complications after GVE with coils in patients with PeVD. Methods: This retrospective cohort study included 150 female patients with PeVD who underwent GVE with coils in 2000–2020. A total of 4975 patients with chronic pelvic pain (CPP) were examined, of which 1107 patients had the PeVD-related CPP and 305 underwent surgical or endovascular interventions on the gonadal veins. Complication rates were evaluated 30 days after GVE and classified according to the Society for Interventional Radiology (SIR) adverse event classification system. The pain severity before and after GVE was assessed using a visual analogue scale (VAS). All patients underwent duplex ultrasound after GVE, while patients with persisting pain syndrome and suspected perforation of the gonadal vein were also evaluated using computed tomographic venography. Results: At 30 days after GVE, the CPP was decreased in 109 (72.6%) patients (from 8.2 ± 1.5 at baseline to 1.7 ± 0.8 scores, p = 0.0001) and persisted in 41 (27.4%) patients (mean change from 8.1 ± 0.7 at baseline to 7.8 ± 0.4 scores; p = 0.71). Post-embolic syndrome (PES) occurred in 22% of patients and was completely resolved in 1 month after GVE. The efficacy of GVE in the CPP relief after resolving PES was 94.6%. The GVE complications were identified in 52 (34.6%) patients. Minor complications included access-site hematoma (4%) and allergic reactions (1.3%), and major complications included protrusion of coils (5.3%), thrombosis of the parametrial/uterine veins (21.3%) and deep veins of the calf (2.7%). Conclusions: Gonadal vein embolization with coils in the treatment of PeVD is associated with the development of specific complications and adverse events. The most common complication was pelvic vein thrombosis. Post-embolization syndrome should be considered as an adverse event of this procedure.